A cute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS) are life-threatening critical care syndromes with limited treatment options. Despite numerous promising therapies in preclinical studies (1) (2) (3) (4) (5) , translation to clinical benefit has been elusive. Alternatively, the identification of effective prevention strategies may prove more effective in addressing this serious condition. However, with the exception of lung protective ventilation strategies (6 -8) and conservative transfusion practices (8 -10) , effective preventive interventions are also lacking.
Platelet activation has been linked to numerous biologic processes beyond hemostasis such as inflammatory reactions, vascular permeability, and altered immune function (11, 12) . Accumulating evidence also suggests an active role for platelets in both ALI pathogenesis (13) (14) (15) and resolution (16 -18) . Preclinical data suggests that aspirin (ASA) can modulate many of the platelet-mediated processes involved in ALI development (15, 19, 20) and resolution (21, 22) . We recently confirmed a potential preventive role for antiplatelet therapy in patients at high risk for ALI (23) . However, this investigation had several important limitations because the study population was homogeneous and it was performed in a single academic medical center.
The objective of the current investigation was to further define the association between prehospitalization ASA therapy and the development of ALI in a heterogeneous population of patients at high risk for ALI with appropriate adjustment for potentially confounding variables. We hypothesized that in this more diverse study population, prehospitalization ASA therapy would remain associated with a reduced incidence of ALI/ARDS.
MATERIALS AND METHODS
This is a secondary analysis of a multicenter, prospective cohort investigation. The prospective study was approved by the institutional review board at each participating institution. Approval was also granted for ancillary studies such as the present investigation. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were followed in the design and reporting of this observational study (24) .
Study Population. Details of the study population have been previously described (25) . Briefly, consecutive adult patients were enrolled prospectively in 19 hospitals and retrospectively (after hospital discharge) in three hospitals over a 6-month period beginning in March 2009. Participating institutions included both community and academic medical centers. Twenty of the included hospitals were located in the United States with two additional institutions located in Turkey. Inclusion criteria consisted of admission to the hospital with the presence of at least one major risk factor for ALI and age Ͼ18 yrs. Variables considered major risk factors for ALI included aspiration, pneumonia, sepsis, shock, pancreatitis, high-risk trauma, or high-risk surgery. For the present investigation, surgical patients were excluded as a result of the frequent discontinuation of antiplatelet agents before elective surgery and an inability to reliably determine the presence or absence of ASA therapy at the time of hospital admission. The remaining risk factors needed to be present at the time of hospital admission to be considered. Standardized definitions were used to identify these risk factors (high-risk trauma [26, 27] , aspiration [26, 28] , sepsis [11, 29] , shock [29, 30] , pneumonia [26, 29] , and pancreatitis [29, 31] ). Cardiogenic shock was not included as a major risk factor for ALI and was not sufficient for inclusion in this study. Patients were excluded if they presented to the hospital with ALI (prevalent ALI), if they were transferred from an outside hospital, died in the emergency department, or were admitted for comfort or hospice care. Hospital readmissions during the study period were also excluded.
Predictor Variables. The exposure of interest was ASA therapy at the time of hospital admission. ASA therapy was defined as documentation of use or administration of any ASA-containing medication at the time of hospital admission in the medical record. Baseline characteristics, including demographics, comorbidities, and other clinical characteristics, were also collected during the first 6 hrs after initial emergency department evaluation by review of the study participant's medical record. ALI/ARDS risk factors and potential risk modifiers were extracted and the predicted risk of ALI was determined using the Lung Injury Prediction Score (25) . This validated score weighs the following variables to calculate a predicted risk of developing ALI while in the hospital: aspiration, pneumonia, sepsis, shock, high-risk surgery, high-risk trauma, alcohol abuse (32, 33) , obesity (body mass index Ͼ30 kg/m 2 ) (34), hypoalbuminemia (26, 35) chemotherapy (36, 37) , FIO 2 Ͼ35% (38), tachypnea (respiratory rate Ͼ30 breaths/min) (26, 36) , SpO 2 Ͻ95%, acidosis (pH Ͻ7.35) (26), and diabetes mellitus (only in patients with sepsis) (26, 39) . Standardized definitions were used to identify these variables (see Supplemental Digital Content 1, http://links.lww.com/CCM/A287). Allocation of the presence of ASA therapy and additional variables of interest was performed by a member of the study staff at each participating institution. Investigators and study coordinators at each site reviewed the studies' standard operating procedures and received structured online training for definitions of each risk factor before study initiation. The Acute Physiology and Chronic Health Evaluation (APACHE) II score was recorded as a measure of severity of illness. In the three hospitals that collected data retrospectively, the investigators followed the same protocols and definitions, but data were collected after hospital discharge.
Outcome Variable. The primary outcome was development of ALI or ARDS during the hospitalization. Standard American-European consensus conference (40) criteria were used for determination of ALI and ARDS. Specifically, to be allocated a diagnosis of ALI, the following elements were required: development of acute, bilateral pulmonary infiltrates on chest radiograph, a PaO 2 /FIO 2 ratio Յ300 (Յ200 for ARDS), and absence of signs for left atrial hypertension as the main explanation for pulmonary edema. All of these diagnostic criteria needed to be present during the same 24-hr epoch to meet criteria for ALI. The adjudication of ALI/ARDS diagnoses were made locally at each participating site by a member of the study team. Investigators and study coordinators at each site underwent a structured online tutorial for the assessment of ALI before study initiation. Secondary outcome measures included intensive care unit (ICU) and hospital mortality and ICU and hospital length of stay.
Statistical Analysis. Assuming a baseline ALI frequency of 6.2% and a 25% rate of ASA administration (data from the study population), the sample size required to identify an odds ratio of 0.5 with ASA administration was calculated to be 2194 (two-sided ␣ ϭ 0.05, ␤ ϭ 0.20). For comparisons of putative prognostic factors between participants that received ASA and those that did not, standard descriptive and inferential methods were used. Dichotomous variables are presented as counts with percentages. Continuous data are presented as median with 25% to 75% interquartile ranges. Comparisons between the two groups were performed with a Pearson's chisquare test or Fisher's exact test as appropriate for categorical variables. Continuous variables were tested with the Mann-Whitney rank-sum test and the Kruskal-Wallis test, as appropriate. To further evaluate the association between ASA therapy and lung injury, a sensitivity analysis was performed assessing the association between ASA and ARDS (cases only meeting criteria for ALI were excluded).
Observational studies risk unequal distributions of important covariates between treatment groups because random assignment is not used. Thus, a propensity score analysis was performed. The propensity score, that is the probability of receiving ASA therapy, was calculated from a multiple logistic regression model. Covariates that were missing in a substantial portion of the study population were not included in the model (ethnicity, obesity, alcohol abuse, smoking status). Data were not available for many potential indications for ASA administration (coronary artery disease, cerebrovascular disease, peripheral vascular disease, hypertension). To address this limitation and to improve the performance of the propensity model, we included therapies often prescribed for these specific diagnoses (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, statins, amiodarone). The variables included in the propensity model were age; gender; diabetes mellitus; cirrhosis; chronic kidney disease, stage V; congestive heart failure, New York Heart Association class IV; chronic obstructive lung disease; gastroesophageal reflux disease; immunosuppression; prehospitalization administration of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, statins, and/or amiodarone; and admission source. To further test the hypothesis that ASA was protective for the development of ALI, the Cochran-Mantel-Haenszel estimate of the pooled odds ratio was determined after stratifying the ASA propensity scores into equally sized deciles. This approach allowed full use of the data and also provided stratum-by-stratum estimates of the ASA odds ratio to better understand the association with ALI.
Importantly, the empiric distributions of propensity scores were inherently different between the ASA-treated and nontreated patients. To address this issue more fully, a sensitivity analysis was performed matching ASA-exposed patients to nonexposed patients based on propensity score. A 0.1 caliper of propensity was used when identifying each ASA-exposed patient's nonexposed control(s). When possible, two nonexposed patients were matched to each ASA-exposed study participant. When a second nonexposed match could not be identified, a single ASA nonexposed match was accepted for the analysis. If no match could be identified for an ASA-exposed patient, the patient was excluded from the analysis. Conditional logistic regression was used to estimate the ASA treatment effect while conditioning on each matched set of case and control(s) (stratum).
All statistical analyses were performed using JMP statistical software base version 8.0 and SAS 9.1.4 (SAS Institute Inc, Cary, NC).
RESULTS
A total of 3855 patients met the inclusion and exclusion criteria and were included in this investigation. The flow of patient evaluation, exclusion, and enrollment are shown in Figure 1 . A total of 976 (25.3%) were receiving ASA at the time of hospitalization. Demographic and baseline information are presented in Table 1. Patients taking ASA were older, more frequently white, and resided in a nursing home with greater frequency than non-ASA users. ASA users were more severely ill (higher APACHE II) at the time of hospital admission but had similar estimated risk for developing ALI (similar Lung Injury Prediction Score). The ASA cohort had a greater frequency of pneumonia as the major risk for ALI, whereas the non-ASA cohort had a higher frequency of lung contusion as a major risk factor. Differences in ALI risk modifiers between ASA users and nonusers can be seen in Table 1 . Specifically, ASA users had more prevalent diabetes mellitus, chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, and gastroesophageal reflux disease, whereas the non-ASA group had a greater frequency of cirrhosis. ASA users were also more frequently obese and more frequently receiving angiotensinconverting enzyme inhibitors/angiotensin II receptor blockers and statin therapy. In contrast, non-ASA users were more frequently receiving amiodarone and immunosuppressive therapy. Alcohol and tobacco use were also more prevalent in the non-ASA cohort.
A total of 240 (6.2%) patients developed ALI during their hospitalization with 159 meeting criteria for ARDS. The median time from hospital admission to American-European consensus conference criteria for ALI/ARDS was 2 days (interquartile range, 2-5). Thirty-six patients developed ALI Ͼ7 days after hospital admission. Four of these were in the ASA cohort. Univariate analyses evaluating patient outcome by the presence of ASA therapy are shown in Table 2 . Patients receiving ASA had a lower incidence of ALI (4.5% vs. 6.8%; odds ratio [OR], 0.65; 95% confidence interval [CI], 0.46 -0.90; p ϭ .010) when compared with those not receiving ASA therapy. Statistical significance remained (OR, 0.65; 95% CI, 0.43-0.98; p ϭ .036) with the sensitivity analysis restricting the outcome to patients who developed ARDS (excluding patients only meeting criteria for ALI, n ϭ 81). No statistically significant differences were noted in ICU or hospital mortality nor ICU or hospital lengths of stay (Table 2) .
A total of 3814 patients were assigned a propensity score. Forty-one (1%) were not assigned a score as a result of missing data. The covariates included in the propensity model are shown in Table 3 and the results of the adjusted analyses stratifying patients by decile of propensity score are shown in Table 4 . In the first strata, no patient receiving prehospitalization ASA therapy developed ALI. Therefore, an OR for ASA could not be determined in this stratum. Overall, some heterogeneity in within-strata ORs was noted with estimates ranging from 0.26 (95% CI, 0.08 -0.81) to 2.55 (95% CI, 0.29 -22.09). Seven of the nine strata with calculable ORs had point estimates for the OR Ͻ1.0 (supportive of the hypothesis that ASA may have a protective effect for the development of ALI). The observed degree of heterogeneity did not lead to rejection of the null hypothesis of homogeneity required to compute the pooled estimate of the OR (Breslow-Day p ϭ .27). Accordingly, the pooled OR as determined by the Cochran-MantelHaenszel test was calculated to be 0.70 (95% CI 0.48 -1.03; p ϭ .072).
Sensitivity Analyses. The propensity score adjustment removed most of the potential confounding associated with baseline differences in ASA users and those not treated with ASA (propensity score adjusted p values, Table 1 ). After adjusting by propensity score decile, only age, APACHE II score, use of statins, and lung contusion remained statistically different between the groups. Age, APACHE II score, and statin use were all positively correlated, whereas the occurrence of lung contusion was negatively associated with this set of characteristics. To investigate if the residual differences in group characteristics affected the estimation of the ASA main effect, additional conditional logistic regression models were specified. Given the intercorrelation of the four variables, sensitivity models that modeled the ASA indicator along with each individual variable were considered (note: propensity score decile was still used as the stratification variable in the conditional logistic regression models).
The four sensitivity models that adjusted for propensity score decile and the residual potential confounding variable yielded similar results to the primary analysis with one exception. A second approach to the sensitivity analyses was developed that directly matched ASA users to nonusers based on caliper matching of the propensity score. The conditional logistic regression evaluation of the association between ASA and development of ALI/ARDS, matching ASA-exposed patients to nonexposed patients by propensity score, was performed as outlined previously. A total of 815 ASAexposed were matched to 1221 nonexposed patients (409 ASA-exposed had a single nonexposed match, whereas 406 had two matches). There were 144 ASAexposed patients for whom no match could be found. These individual's propensity scores averaged 0.71 with a minimum value of 0.51 and a maximum value of 0.91. An additional 1634 nonexposed subjects were unmatched and therefore not included in this sensitivity analysis. The remaining number (percent) of ALI cases was 34 (4.17%) in the ASA-exposed cohort and 78 (6.39%) in the nonexposed group. In the conditional logistic regression analysis, the association between ASA treatment and ALI did not meet statistical significance (OR, 0.67; 95% CI, 0.44 -1.01; p ϭ .055).
Importantly, the short interval between hospital admission and development of ALI (median, 2 days; interquartile range, 2-5 days) raises the possibility that some patients may have been progressing to the full phenotype of ALI at the time of hospital admission (prevalent ALI) rather than having experienced incident ALI. In this circumstance, ASA may not be an effective therapeutic agent. To address this potential bias, we performed a sensitivity analysis evaluating the association between ASA therapy and ALI in the subgroup of patients who developed lung injury Ͼ2 days after hospital admission (n ϭ 129). When adjusting for the propensity to receive ASA therapy, modeled as a covariate in a logistic regression model, the association between ASA and development of ALI was nonsignificant (adjusted OR, 0.84; 95% CI, 0.50 -1.38; p ϭ .13). A final sensitivity analysis was performed to further detail the association between ASA therapy and development of more severe lung injury (ARDS cases only; ALI cases excluded) adjusting for the ASA propensity score modeled as a covariate in a logistic regression model. The effect estimate for this analysis was consistent with the primary analysis with an adjusted OR (95% CI) of 0.71 (0.44 -1.11). 
DISCUSSION
In this investigation, we aimed to better define the association between prehospitalization ASA therapy and ALI/ ARDS. To this end, initial univariate analyses supported the hypothesis of a protective effect with ASA therapy in patients at risk of ALI. However, inherent differences in the patients who received ASA, when compared with those who did not, limit the interpretation of this finding. To address this concern, propensity to receive ASA was incorporated into the analysis. Although the magnitude of the estimated effect remained clinically relevant and consistent with the unadjusted analyses, statistical significance was no longer present. No association between prehospitalization ASA therapy and ICU or hospital mortality nor ICU or hospital lengths of stay was observed.
ALI is a multifactorial disease in which immune cell migration and activation within the lung ultimately results in injury to the alveolar-capillary membrane (14, 41, 42) . Mechanistically, endothelial injury/activation is known to result in platelet activation with resultant secretion of platelet granule contents, changes in platelet shape, and upregulated expression of adhesion molecules such as Pselectin (13, 43) . This process has been shown to result in enhanced thromboxane A2 production (44), platelet aggregation (44) , and secondary leukocyte capture (44, 45) , leading to the full phenotype of ALI.
The key role of platelets in the pathogenesis of lung injury presents an opportunity for modulation with antiplatelet therapies such as ASA. In support of this hypothesis, blockade of P-selectin has been shown to reduce neutrophil recruitment and to have a protective effect in acid-induced ALI (44) . Additionally, a study by Looney et al recently evaluated ASA's potential for lung protection in a two-hit animal model of transfusionrelated ALI (15) . When compared with untreated animals, mice that received ASA before insult had marked reductions in plasma thromboxane B 2 production, lower extravascular lung water values, and improved survival. Preclinical data suggest ASA may also enhance the resolution of ALI by promoting the generation of anti-inflammatory lipids such as lipoxin A 4 and 15-epilipoxin A 4 (16, 17, 46) . A growing body of clinical evidence suggests the potential to reduce organ dysfunction with ASA as well. Administration of antiplatelet therapy before hospital admission has recently been associated with improved organ function and reduced mortality in patients requiring intensive care unit support (47) . More recently, our group confirmed an association between prehopsitalization ASA administration and a reduced rate of ALI in a population-based cohort study of ICU patients at high risk of ALI (23) .
Multiple potentially important factors may have contributed to our inability to reject the null hypothesis (no association between ASA therapy and incident ALI). First, the present investigation included multiple institutions (academic and community-based) with no standardized care processes between centers. The lack of standardization likely resulted in variable application of potentially important ALIrelated healthcare delivery factors such as medication administration, nutritional support, conservative transfusion practices and fluid strategies, aspiration precautions, and ventilator management. Heterogeneity in the application of important care processes is expected to increase the variability of the effect estimate of interest (OR for ALI in ASA and NA, not available. a Boundaries appear disjointed as a result of rounding; b overall (pooled) estimate of the odds ratio estimated by Mantel-Haenszel stratified estimator. For stratum 1, the standard odds ratio was not calculable as a result of the zero cases of acute lung injury in the aspirin-treated patients. The "empiric" odds ratio, which adds 0.5 to all cells in the stratum 1 contingency table, yields a pooled estimate of the odds ratio of 0.77 (0.51-1.14). The Breslow-Day test for homogeneity of the odds ratios had a p value of .27, a value supporting the pooling of odds ratios across strata.
non-ASA users). The resultant widening of the effect estimate CIs may contribute to the lack of statistical significance noted in our adjusted analyses. The study population of the present investigation is also more heterogeneous than that of our recent single-center investigation (23) . The diverse study population may have compromised the internal validity of this study. In addition, the limited number of ALI outcomes in many of the strata included in the Cochran-Mantel-Haenszel test may have contributed to the loss of statistical significance in this analysis. Similarly, the reduction in sample size during the matching process may have also contributed to the loss of statistical significance in the conditional logistic regression analysis as well.
Alternatively, the lack of statistical significance in the present investigation may simply suggest that the association of ASA with attenuation of ALI is not as robust as previously believed. If true, several potential explanations exist. First, platelet activation may not be as central to ALI pathogenesis as previously believed. However, the growing body of literature supporting a central role for platelet activation in the pathogenesis of lung injury would argue against this possibility (13) (14) (15) (16) (17) (18) . Second, ASA may not effectively attenuate platelet activation in patients at risk for ALI. More specifically, the dose of ASA administered in this study may not have been sufficient to suppress platelet activation. ASA dose was not recorded at the time of the initial data extraction and the multicenter international nature of this investigation made post hoc ascertainment of ASA dose unfeasible. Although we are not able to comment on differential effects of the commonly administered ASA doses of 81 mg vs. 325 mg, we do note that low-dose ASA (81 mg daily) has been shown to effectively inhibit platelet thromboxane production and elevate plasma levels of lipoxin A 4 with minimal additional effect at higher doses (48, 49) . Differential effects on the attenuation of lung injury may occur with alternative antiplatelet therapies as well. These data were not collected for this investigation and we cannot comment further on this possibility.
Although the large sample size, prospective multicentered design, and welldefined variable criteria with explicit standard operating procedures are strengths of the present investigation, several limitations deserve note. First, the observational nature of this study creates potential for confounding and bias. Although efforts were made to control for these issues during development of the study design, data collection, and statistical analysis, potential for unmeasured confounding effects remains. The observational study design also precludes the standardization of other important care processes, which could confound the association of interest. An additional limitation is the lack of information regarding ASA dose and medication administration after hospital admission. The extended duration of ASA's effect on platelet function and the short interval from hospital admission to ALI onset (median, 2 days [interquartile range, 2-5 days]) attenuates the potential significance of ASA discontinuation after hospital admission. Finally, our inclusion criteria mandated admission to the hospital. Therefore, our findings may not generalize well to at-risk patients who are not admitted to the hospital.
CONCLUSIONS
In summary, after adjusting for the propensity to receive ASA therapy, we did not identify a statistically significant association between ASA administration and incident ALI. However, the results observed in this study do align qualitatively with a growing body of preclinical data and a recent single-center observational study suggesting lung protection with ASA. The inability to completely remove the effects of confounding from this observational study, coupled with the growing body of literature detailing ASA's efficacy in this setting, supports clinical equipoise and the importance of a randomized clinical trial evaluating ASA's potential for lung protection.
